Cormorant Asset Management LP Sells 1,175,000 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Cormorant Asset Management LP lowered its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 54.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,000,000 shares of the company’s stock after selling 1,175,000 shares during the period. NewAmsterdam Pharma accounts for about 1.6% of Cormorant Asset Management LP’s holdings, making the stock its 15th largest holding. Cormorant Asset Management LP owned 0.88% of NewAmsterdam Pharma worth $35,080,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC boosted its holdings in NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after acquiring an additional 300 shares during the last quarter. Navalign LLC bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at $46,000. Empowered Funds LLC bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at $85,000. Finally, NBC Securities Inc. purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter worth about $86,000. Institutional investors own 89.89% of the company’s stock.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $869,158.57. The trade was a 72.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMS opened at $30.15 on Thursday. NewAmsterdam Pharma Company N.V. has a one year low of $17.63 and a one year high of $42.21. The stock has a 50-day moving average of $33.26 and a 200 day moving average of $33.42. The company has a market capitalization of $3.52 billion, a price-to-earnings ratio of -16.84 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The company had revenue of $3.04 million for the quarter. On average, equities analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on NAMS. HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Needham & Company LLC increased their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Finally, Guggenheim raised their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $48.60.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.